In this article from the Journal of Clinical Oncology, the authors suggest the need for caution and well-conducted trials to systematically address the question of total neoadjuvant therapy (TNT) in rectal cancer, which can lead to overtreatment and unnecessary toxicity without a proven benefit. Despite some of its theoretical advantages, declaring TNT a new standard of care may be premature.